Literature DB >> 11468232

Spectrophotometric microassay for delta-aminolevulinate dehydratase in dried-blood spots as confirmation for hereditary tyrosinemia type I.

A Schulze1, D Frommhold, G F Hoffmann, E Mayatepek.   

Abstract

BACKGROUND: Hereditary tyrosinemia type I (HT) fulfills the criteria for inclusion in neonatal screening programs, but measurement of tyrosine lacks clinical specificity and quantitative assay of succinylacetone is laborious. We developed a semiquantitative assay based on inhibition of delta-aminolevulinate dehydratase (ALA-D) by succinylacetone.
METHODS: Preincubation of 3-mm discs from dried-blood spots and reaction of the enzyme with delta-aminolevulinic acid as substrate were performed in microtiter plates. After separation of the supernatant and 10 min of color reaction with modified Ehrlich reagent, the formation of porphobilinogen was measured at 550 nm in a plate reader.
RESULTS: The detection limit for succinylacetone was 0.3 micromol/L; imprecision (CV) was <5.5% within-run and 10-16% between-run. Storage of blood spots at ambient temperature for several days led to a significant decrease of ALA-D activity. Enzyme activity was lost in filter cards at 45 degrees C, but remained stable at 2-37 degrees C. Enzyme activity was decreased in EDTA blood. The absorbance at 550 nm was 0.221 (+/- 0.073) in healthy neonates and 0.043-0.100 in 11 patients with HT. All neonates with increased tyrosine (above the 99.5th centile) in neonatal screening (97 of 47 000) had normal results by the new assay.
CONCLUSIONS: The spectrophotometric microassay for ALA-D is a simple and sensitive test for HT. This represents a basis for further examination of its general reliability as a confirmatory test if tyrosine is found to be increased.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468232

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.

Authors:  Víctor R De Jesús; Barbara W Adam; Daniel Mandel; Carla D Cuthbert; Dietrich Matern
Journal:  Mol Genet Metab       Date:  2014-07-17       Impact factor: 4.797

2.  Transposase-derived proteins FHY3/FAR1 interact with PHYTOCHROME-INTERACTING FACTOR1 to regulate chlorophyll biosynthesis by modulating HEMB1 during deetiolation in Arabidopsis.

Authors:  Weijiang Tang; Wanqing Wang; Dongqin Chen; Qiang Ji; Yanjun Jing; Haiyang Wang; Rongcheng Lin
Journal:  Plant Cell       Date:  2012-05-25       Impact factor: 11.277

3.  Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases.

Authors:  Cindy E L Lim; Klaus I Matthaei; Anneke C Blackburn; Richard P Davis; Jane E Dahlstrom; Mark E Koina; M W Anders; Philip G Board
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

4.  Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1.

Authors:  Jan-Ulrich Schlump; Ertan Mayatepek; Ute Spiekerkoetter
Journal:  Eur J Pediatr       Date:  2009-10-08       Impact factor: 3.183

5.  Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007).

Authors:  D Matern; S Tortorelli; D Oglesbee; D Gavrilov; P Rinaldo
Journal:  J Inherit Metab Dis       Date:  2007-07-23       Impact factor: 4.982

6.  Clinical experience with hepatorenal tyrosinemia from a single Egyptian center.

Authors:  Hanaa El-Karaksy; Hala Mohsen Abdullatif; Carolyne Morcos Ghobrial; Engy Adel Mogahed; Noha Adel Yasin; Noha Talal; Mohamed Rashed
Journal:  PLoS One       Date:  2022-05-10       Impact factor: 3.752

7.  A Rapid Screening Test on Dried Blood for the Neonatal Diagnosis of Tyrosinemia Type I.

Authors:  Farahnaz Bodaghkhan; Bita Geramizadeh; Abbas Abdollah Rajeh; Mahmoud Haghighat; Mohsen Dehghani; Naser Honar; Mojgan Zahmatkeshan; Mohammad-Hadi Imanieh
Journal:  Iran J Pediatr       Date:  2016-02-27       Impact factor: 0.364

8.  A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.

Authors:  David Cassiman; Renate Zeevaert; Elisabeth Holme; Eli-Anne Kvittingen; Jaak Jaeken
Journal:  Orphanet J Rare Dis       Date:  2009-12-15       Impact factor: 4.123

9.  Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.

Authors:  Sebene Mayorandan; Uta Meyer; Gülden Gokcay; Nuria Garcia Segarra; Hélène Ogier de Baulny; Francjan van Spronsen; Jiri Zeman; Corinne de Laet; Ute Spiekerkoetter; Eva Thimm; Arianna Maiorana; Carlo Dionisi-Vici; Dorothea Moeslinger; Michaela Brunner-Krainz; Amelie Sophia Lotz-Havla; José Angel Cocho de Juan; Maria Luz Couce Pico; René Santer; Sabine Scholl-Bürgi; Hanna Mandel; Yngve Thomas Bliksrud; Peter Freisinger; Luis Jose Aldamiz-Echevarria; Michel Hochuli; Matthias Gautschi; Jessica Endig; Jens Jordan; Patrick McKiernan; Stefanie Ernst; Susanne Morlot; Arndt Vogel; Johannes Sander; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-08-01       Impact factor: 4.123

Review 10.  Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.

Authors:  Jeffrey M Chinsky; Rani Singh; Can Ficicioglu; Clara D M van Karnebeek; Markus Grompe; Grant Mitchell; Susan E Waisbren; Muge Gucsavas-Calikoglu; Melissa P Wasserstein; Katie Coakley; C Ronald Scott
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.